Fuad El-Hibri is Chairman at Emergent BioSolutions Inc. (EBS). They have made 56 open-market trades across 2 companies since 2008, most recently 2021-12-03.
CIK 0001380185
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
10 open-market purchases totalling $249K since 2019, against 46 sales. Across 10 scored buys the stock is down 28.6% at ninety days, and 28.6 points behind the S&P over the same stretch.
10 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 50% | 0% | 0% |
| Avg Move | +0.1% | -13.3% | -28.6% |
| Alpha | +1.2% | -10.7% | -28.6% |
| Scored | 10 | 10 | 10 |
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 86% | 100% | 100% |
| Avg Move | -8.9% | -11.8% | -20.0% |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EBS | SELL | 2020-11-09 | 2020-11-12 | $90.61 | $5.3M | -8.5% | +0.3% | +38.6% |
| EBS | SELL | 2020-11-02 | 2020-11-04 | $90.59 | $3.6M | -12.6% | -16.5% | +17.7% |
| EBS | SELL | 2020-09-23 | 2020-09-25 | $99.44 | $3.8M | +6.3% | -6.8% | -8.3% |
| EBS | SELL | 2020-09-16 | 2020-09-18 | $101.28 | $6.1M | +4.4% | -3.0% | -4.0% |
| EBS | SELL | 2020-09-09 | 2020-09-11 | $102.73 | $4.1M | +2.5% | +11.8% | -16.4% |
| EBS | SELL | 2020-04-29 | 2020-05-01 | $74.13 | $3.0M | +3.4% | +13.7% | +23.6% |
| EBS | SELL | 2020-04-22 | 2020-04-24 | $67.65 | $2.7M | +1.3% | +7.1% | +13.4% |
| EBS | SELL | 2020-04-16 | 2020-04-20 | $62.47 | $1.2M | +7.3% | +28.6% | +48.1% |
| EBS | SELL | 2020-04-13 | 2020-04-15 | $62.49 | $4.5M | +26.7% | +34.4% | +55.9% |
| EBS | SELL | 2020-04-08 | 2020-04-10 | $61.48 | $6.7M | +6.1% | +34.7% | +50.6% |
| EBS | SELL | 2020-04-06 | 2020-04-08 | $60.63 | $3.5M | +5.5% | +27.2% | +41.0% |
| EBS | SELL | 2020-02-26 | 2020-02-28 | $57.97 | $2.7M | -10.5% | -8.0% | +38.4% |
| EBS | SELL | 2020-02-20 | 2020-02-24 | $64.90 | $3.0M | -2.9% | -12.7% | +34.1% |
| EBS | SELL | 2020-02-14 | 2020-02-19 | $63.90 | $2.6M | -8.4% | -23.2% | +34.6% |
| EBS | SELL | 2020-02-11 | 2020-02-13 | $62.90 | $1.3M | -7.5% | -9.2% | +28.5% |
| EBS | SELL | 2020-02-05 | 2020-02-07 | $60.90 | $7.3M | +6.0% | -13.8% | +30.1% |
| APVO | BUY | 2019-08-12 | 2019-08-13 | $0.76 | $76K | +0.2% | -10.6% | -5.5% |
| APVO | BUY | 2019-07-29 | 2019-07-30 | $0.83 | $46K | -1.4% | -23.6% | -34.4% |
| APVO | BUY | 2019-07-23 | 2019-07-24 | $0.90 | $9K | -2.6% | -20.2% | -29.2% |
| APVO | BUY | 2019-07-22 | 2019-07-23 | $0.89 | $27K | +5.5% | -12.7% | -27.4% |
| APVO | BUY | 2019-07-19 | 2019-07-19 | $0.90 | $24K | +1.0% | -8.1% | -27.2% |
| APVO | BUY | 2019-07-18 | 2019-07-18 | $0.87 | $13K | -2.4% | -8.6% | -28.3% |
| APVO | BUY | 2019-07-17 | 2019-07-18 | $0.87 | $17K | -2.4% | -8.6% | -28.3% |
| APVO | BUY | 2019-07-16 | 2019-07-16 | $0.85 | $10K | -2.2% | -15.9% | -35.5% |
| APVO | BUY | 2019-07-11 | 2019-07-12 | $0.85 | $12K | +3.7% | -13.5% | -35.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| Scored | 7 | 7 | 7 |